60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis

Company Overview

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Key Stats

• Today's Range: $1.62 to $1.69
• 50-Day Range: $1.42 to $3.22
• 52-Week Range: $1.29 to $14.68
• Volume: 44,197 shs
• Average Volume: 3.29 million shs
• Market Capitalization: $4.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.10
• Consensus Rating: Hold

60 Degrees Pharmaceuticals Stock Analysis - MarketRank™

60 Degrees Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

60 Degrees Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

60 Degrees Pharmaceuticals has a consensus price target of $14.10, representing about 749.4% upside from its current price of $1.66.

Amount of Analyst Coverage

60 Degrees Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($2.70) to ($0.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 60 Degrees Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 60 Degrees Pharmaceuticals is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.03% of the float of 60 Degrees Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 0.69, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 60 Degrees Pharmaceuticals has recently increased by 13.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

60 Degrees Pharmaceuticals does not currently pay a dividend.

Dividend Growth

60 Degrees Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.49

News Sentiment

60 Degrees Pharmaceuticals has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for 60 Degrees Pharmaceuticals this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for SXTP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

5 people have added 60 Degrees Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, 60 Degrees Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.69% of the stock of 60 Degrees Pharmaceuticals is held by insiders.

Percentage Held by Institutions

7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions.

SXTP Stock Analysis - Frequently Asked Questions

How have SXTP shares performed this year?

60 Degrees Pharmaceuticals' stock was trading at $2.0332 at the start of the year. Since then, SXTP stock has decreased by 18.4% and is now trading at $1.66.

How were 60 Degrees Pharmaceuticals' earnings last quarter?

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) released its quarterly earnings data on Thursday, November, 13th. The company reported ($2.64) EPS for the quarter, topping the consensus estimate of ($4.84) by $2.20. The company earned ($0.01) million during the quarter, compared to the consensus estimate of $0.38 million.

When did 60 Degrees Pharmaceuticals' stock split?

60 Degrees Pharmaceuticals's stock reverse split on Tuesday, January 20th 2026.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 19th 2026. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

When did 60 Degrees Pharmaceuticals IPO?

60 Degrees Pharmaceuticals (SXTP) raised $7 million in an IPO on Wednesday, July 12th 2023. The company issued 1,400,000 shares at $5.30 per share. WallachBeth Capital LLC acted as the underwriter for the IPO.

How do I buy shares of 60 Degrees Pharmaceuticals?

Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of 60 Degrees Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 60 Degrees Pharmaceuticals investors own include Recursion Pharmaceuticals (RXRX), Editas Medicine (EDIT), Pacific Biosciences of California (PACB), Tilray Brands (TLRY), Akanda (AKAN), Better Therapeutics (BTTX) and Honeywell International (HON).

Company Calendar

• Last Earnings: 11/13/2025
• Today: 5/06/2026
• Next Earnings (Estimated): 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SXTP
• CIK: 1946563
• Web: 60degreespharma.com
• Phone: 202-327-5422
• Fax: N/A
• Employees: 3
• Year Founded: 2010

Price Target and Rating

• Average Price Target for 60 Degrees Pharmaceuticals: $14.10
• High Price Target: $24.00
• Low Price Target: $4.20
• Potential Upside/Downside: +749.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($13.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.36 million
• Net Margins: -550.67%
• Pretax Margin: -522.92%
• Return on Equity: N/A
• Return on Assets: -132.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.66
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $1.41 million
• Price / Sales: 3.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($5.85) per share
• Price / Book: -0.28

Miscellaneous

• Outstanding Shares: 2,640,000
• Free Float: 2,592,000
• Market Cap: $4.38 million
• Optionable: Not Optionable
• Beta: 2.69